Clinical trial NCT05933577: A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
Official title: A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma (INTerpath-001)
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE3
Conditions: Melanoma
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
Collaborators: name: ModernaTX, Inc.
First posted: 2023-07-06
Enrollment: 1089
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to learn if intismeran autogene which is an individualized neoantigen therapy (INT; formerly, called messenger ribonucleic acid \[mRNA\]-4157) with pembrolizumab (MK-3475) is safe and prevents cancer from returning in people with high-risk melanoma. Researchers want to know if intismeran autogene with pembrolizumab is better than receiving pembrolizumab alone at preventing the cancer from returning.


Eligibility criteria: Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

* Has surgically resected and histologically/pathologically confirmed diagnosis of Stage IIB or IIC, III, or IV cutaneous melanoma
* Has not received any prior systemic therapy for their melanoma beyond surgical resection
* No more than 13 weeks have passed between final surgical resection that rendered the participant disease-free and the first dose of pembrolizumab
* Is disease free at the time of providing documented consent for the study
* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy (ART)

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

* Has ocular or mucosal melanoma
* Has cancer that has spread to other parts of the body and cannot be removed with surgery
* Has heart failure within the past 6 months
* Has received prior cancer therapy or another cancer vaccine
* Has another known cancer that that has spread to other parts of the body or has required treatment within the past 3 years
* Has severe reaction to study medications or any of their substance used to prepare a drug
* Have not recovered from major surgery or have ongoing surgical complications

Primary outcomes:
measure: Recurrence-Free Survival (RFS)
timeFrame: Up to approximately 74 months
Secondary outcomes:
measure: Distant Metastasis-Free Survival (DMFS)
timeFrame: Up to approximately 85 months
measure: Overall-Survival (OS)
timeFrame: Up to approximately 85 months
measure: Number of Participants Who Experience an Adverse Event (AE)
timeFrame: Up to approximately 68 weeks
measure: Number of Participants Who Discontinue Study Treatment Due to an AE
timeFrame: Up to approximately 56 weeks
measure: Change from Baseline in the European Organization for Research and Treatment of Cancer (EORTC)-Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status/Quality of Life (Items 29 and 30) Combined Score
timeFrame: Baseline and up to approximately 85 months
measure: Change from Baseline in the EORTC QLQ-C30 Physical Functioning (Items 1-5) Combined Score on the EORTC QLQ-C30
timeFrame: Baseline and up to approximately 85 months
measure: Change from Baseline in the EORTC QLQ-C30 Role Functioning (Items 6 and 7) Combined Score on the EORTC QLQ-C30
timeFrame: Baseline and up to approximately 85 months
Other outcomes:
Locations:
city: Springdale
country: United States
facility: Highlands Oncology Group ( Site 1943)
state: Arkansas
city: Los Angeles
country: United States
facility: UCLA Hematology/Oncology - Westwood (Building 100) ( Site 1918)
state: California
city: San Francisco
country: United States
facility: UCSF Medical Center at Mission Bay ( Site 1929)
state: California
city: New Haven
country: United States
facility: Yale-New Haven Hospital-Yale Cancer Center ( Site 1933)
state: Connecticut
city: Orlando
country: United States
facility: Orlando Health Cancer Institute ( Site 1937)
state: Florida
city: Tampa
country: United States
facility: Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center ( Site 1945)
state: Florida
city: Atlanta
country: United States
facility: Winship Cancer Institute of Emory University ( Site 1940)
state: Georgia
city: Marietta
country: United States
facility: Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 1950)
state: Georgia
city: Iowa City
country: United States
facility: University of Iowa-Holden Comprehensive Cancer Center ( Site 1935)
state: Iowa
city: Baltimore
country: United States
facility: Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center - Melanoma ( Site 1912)
state: Maryland
city: Boston
country: United States
facility: Massachusetts General Hospital ( Site 1927)
state: Massachusetts
city: Boston
country: United States
facility: Beth Israel Deaconess Medical Center ( Site 1957)
state: Massachusetts
city: Boston
country: United States
facility: Dana-Farber Cancer Institute ( Site 1956)
state: Massachusetts
city: Ann Arbor
country: United States
facility: University of Michigan ( Site 1915)
state: Michigan
city: Grand Rapids
country: United States
facility: Cancer and Hematology Centers of Western Michigan ( Site 1932)
state: Michigan
city: Hackensack
country: United States
facility: John Theurer Cancer Center at Hackensack University Medical Center ( Site 1944)
state: New Jersey
city: Morristown
country: United States
facility: Atlantic Health System ( Site 1925)
state: New Jersey
city: Ridgewood
country: United States
facility: Valley Health Systems - Ridgewood Campus ( Site 1947)
state: New Jersey
city: Mineola
country: United States
facility: Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 1958)
state: New York
city: New York
country: United States
facility: NYU Langone Health-Perlmutter Cancer Center ( Site 1917)
state: New York
city: New York
country: United States
facility: Columbia University Irving Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical
state: New York
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center ( Site 1914)
state: New York
city: Chapel Hill
country: United States
facility: University of North Carolina Medical Center-Lineberger Comprehensive Cancer Center ( Site 1949)
state: North Carolina
city: Durham
country: United States
facility: Duke Cancer Institute ( Site 1911)
state: North Carolina
city: Philadelphia
country: United States
facility: Hospital of the University of Pennsylvania Perelman Center for Advanced Medicine ( Site 1905)
state: Pennsylvania
city: Pittsburgh
country: United States
facility: UPMC Hillman Cancer Center ( Site 1909)
state: Pennsylvania
city: Charleston
country: United States
facility: Medical University of South Carolina-Hollings Cancer Center ( Site 1934)
state: South Carolina
city: Sioux Falls
country: United States
facility: Sanford Cancer Center ( Site 1951)
state: South Dakota
city: Nashville
country: United States
facility: SCRI Oncology Partners ( Site 1910)
state: Tennessee
city: Austin
country: United States
facility: Texas Oncology - Austin ( Site 1903)
state: Texas
city: Dallas
country: United States
facility: Texas Oncology - Dallas (Sammons) ( Site 1902)
state: Texas
city: Houston
country: United States
facility: University of Texas MD Anderson Cancer Center ( Site 1920)
state: Texas
city: Fairfax
country: United States
facility: Inova Schar Cancer Institute ( Site 1900)
state: Virginia
city: Seattle
country: United States
facility: Fred Hutchinson Cancer Center ( Site 1901)
state: Washington
city: Caba
country: Argentina
facility: Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 2202)
state: Buenos Aires
city: Ciudad Autónoma de Buenos Aires
country: Argentina
facility: Instituto Alexander Fleming-Alexander Fleming ( Site 2203)
state: Caba
city: Río Cuarto
country: Argentina
facility: Centro Privado de RMI Río Cuarto S.A. II ( Site 2201)
state: Cordoba
city: Buenos Aires
country: Argentina
facility: Hospital Aleman ( Site 2200)
city: Buenos Aires
country: Argentina
facility: Sanatorio Finochietto ( Site 2205)
city: Caba
country: Argentina
facility: Clinica Adventista Belgrano-Oncology ( Site 2204)
city: Westmead
country: Australia
facility: Westmead Hospital-Department of Medical Oncology ( Site 1001)
state: New South Wales
city: Wollstonecraft
country: Australia
facility: Melanoma Institute Australia-Clinical Trials Unit ( Site 1000)
state: New South Wales
city: Brisbane
country: Australia
facility: Princess Alexandra Hospital ( Site 1003)
state: Queensland
city: Melbourne
country: Australia
facility: Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 1005)
state: Victoria
city: Melbourne
country: Australia
facility: Paula Fox Melanoma & Cancer Centre ( Site 1004)
state: Victoria
city: Nedlands
country: Australia
facility: One Clinical Research ( Site 1002)
state: Western Australia
city: Brussels
country: Belgium
facility: UZ Brussel-Medische oncologie ( Site 3405)
state: Bruxelles-Capitale, Region De
city: Genk
country: Belgium
facility: Ziekenhuis Oost-Limburg, Campus St.-Jan ( Site 3402)
state: Limburg
city: Gent
country: Belgium
facility: UZ Gent ( Site 3403)
state: Oost-Vlaanderen
city: Leuven
country: Belgium
facility: UZ Leuven ( Site 3400)
state: Vlaams-Brabant
city: Kortrijk
country: Belgium
facility: AZ Groeninge Campus Kennedylaan-Oncology ( Site 3401)
state: West-Vlaanderen
city: Belo Horizonte
country: Brazil
facility: Centro Avançado de Tratamento Oncológico- CENANTRON ( Site 2303)
state: Minas Gerais
city: Ijui
country: Brazil
facility: ONCOSITE - Centro de Pesquisa Clinica em Oncologia ( Site 2302)
state: Rio Grande Do Sul
city: Porto Alegre
country: Brazil
facility: Hospital Nossa Senhora da Conceição ( Site 2309)
state: Rio Grande Do Sul
city: Rio de Janeiro
country: Brazil
facility: Instituto Nacional de Câncer - INCA-Pesquisa Clinica HC II ( Site 2305)
city: Sao Paulo
country: Brazil
facility: ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 2300)
city: Edmonton
country: Canada
facility: Cross Cancer Institute ( Site 1104)
state: Alberta
city: Vancouver
country: Canada
facility: BC Cancer Vancouver-Clinical Trials Unit ( Site 1106)
state: British Columbia
city: Brampton
country: Canada
facility: William Osler Health System ( Site 1105)
state: Ontario
city: Toronto
country: Canada
facility: Sunnybrook Research Institute ( Site 1103)
state: Ontario
city: Toronto
country: Canada
facility: Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 1102)
state: Ontario
city: Montréal
country: Canada
facility: Centre Hospitalier de l'Université de Montréal-Unité de Recherche Clinique en Oncologie et Hématolo
state: Quebec
city: Quebec City
country: Canada
facility: Centre intégré de cancérologie du CHU de Québec Université L-Hemato-Oncology ( Site 1101)
state: Quebec
city: Santiago
country: Chile
facility: FALP-UIDO ( Site 2400)
state: Region M. De Santiago
city: Santiago
country: Chile
facility: Clínica UC San Carlos de Apoquindo-Hemato-Oncology ( Site 2402)
state: Region M. De Santiago
city: Santiago
country: Chile
facility: Bradfordhill ( Site 2401)
state: Region M. De Santiago
city: Rionegro
country: Colombia
facility: Clinica Somer-Unidad de Investigacion y Docencia ( Site 2506)
state: Antioquia
city: Montería
country: Colombia
facility: Oncomedica S.A.S ( Site 2503)
state: Cordoba
city: Bogota
country: Colombia
facility: Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia-Center Investigator ( Site 2500)
state: Distrito Capital De Bogota
city: Cali
country: Colombia
facility: Fundación Valle del Lili ( Site 2505)
state: Valle Del Cauca
city: Copenhagen
country: Denmark
facility: Herlev and Gentofte Hospital ( Site 3301)
state: Hovedstaden
city: Aalborg
country: Denmark
facility: Aalborg Universitetshospital, Syd ( Site 3302)
state: Nordjylland
city: Odense C
country: Denmark
facility: Odense Universitetshospital ( Site 3300)
state: Syddanmark
city: Nice cedex 3
country: France
facility: Centre Hospitalier Universitaire de Nice - Hôpital l'Archet-Dermatology Department ( Site 1211)
state: Alpes-Maritimes
city: Marseille
country: France
facility: Assistance Publique Hôpitaux de Marseille - Hôpital de la Ti-Service de Dermatologie et Cancérologi
state: Bouches-du-Rhone
city: Dijon
country: France
facility: Centre Georges François Leclerc ( Site 1210)
state: Cote-d Or
city: Besançon
country: France
facility: CHU Besançon ( Site 1209)
state: Doubs
city: Bordeaux
country: France
facility: CHU de Bordeaux Hop St ANDRE-Service de Dermatologie ( Site 1204)
state: Gironde
city: Rennes
country: France
facility: Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer ( Site 1206)
state: Ille-et-Vilaine
city: Lille
country: France
facility: Hopital Claude Huriez - CHU de Lille ( Site 1207)
state: Nord
city: Pierre-Bénite
country: France
facility: centre hospitalier lyon sud-Service de dermatologie ( Site 1202)
state: Rhone
city: Amiens
country: France
facility: CHU d'Amiens-Picardie - Hôpital Sud-Dermatologie ( Site 1208)
state: Somme
city: Villejuif
country: France
facility: Gustave Roussy-Dermatologie ( Site 1201)
state: Val-de-Marne
city: Paris
country: France
facility: Hôpital Saint-Louis ( Site 1200)
city: Mannheim
country: Germany
facility: Universitätsmedizin Mannheim ( Site 1305)
state: Baden-Wurttemberg
city: Augsburg
country: Germany
facility: Universitaetsklinikum Augsburg ( Site 1312)
state: Bayern
city: München
country: Germany
facility: Klinik und Poliklinik für Dermatologie und Allergologie-Dermato-oncology ( Site 1315)
state: Bayern
city: Rostock
country: Germany
facility: Universitätsmedizin Rostock-Klinik und Poliklinik für Dermatologie und Venerologie ( Site 1310)
state: Mecklenburg-Vorpommern
city: Göttingen
country: Germany
facility: Universitätsmedizin Göttingen - Georg-August-Universität-Dermatology ( Site 1308)
state: Niedersachsen
city: Essen
country: Germany
facility: Universitaetsklinikum Essen-Klinik für Dermatologie, Venerologie und Allergologie ( Site 1300)
state: Nordrhein-Westfalen
city: Köln
country: Germany
facility: Universitaetsklinikum Koeln ( Site 1307)
state: Nordrhein-Westfalen
city: Minden
country: Germany
facility: Johannes Wesling Klinikum Minden-Skin Cancer Center Minden ( Site 1301)
state: Nordrhein-Westfalen
city: Homburg
country: Germany
facility: Universitaetsklinikum des Saarlandes ( Site 1313)
state: Saarland
city: Gera
country: Germany
facility: SRH Wald-Klinikum Gera-Zentrum für klinische Studien ( Site 1306)
state: Thuringen
city: Berlin
country: Germany
facility: Charité Universitaetsmedizin Berlin - Campus Mitte-Hauttumorcentrum Charité (HTCC) ( Site 1302)
city: Hamburg
country: Germany
facility: Universitaetsklinikum Hamburg-Eppendorf ( Site 1309)
city: Athens
country: Greece
facility: General Hospital of Athens "Laiko"-First Department of Internal Medicine ( Site 3700)
state: Attiki
city: Neo Faliro
country: Greece
facility: Metropolitan Hospital-A' Oncology Dpt ( Site 3701)
state: Attiki
city: Thessaloniki
country: Greece
facility: Bioclinic Thessalonikis Private Clinic Single Member S.A.-Oncology ( Site 3703)
state: Kentriki Makedonia
city: Thessaloniki
country: Greece
facility: European Interbalkan Medical Center-Oncology Department ( Site 3702)
city: Afula
country: Israel
facility: Emek Medical Center ( Site 2003)
city: Jerusalem
country: Israel
facility: Hadassah Medical Center ( Site 2004)
city: Petah Tikva
country: Israel
facility: Rabin Medical Center ( Site 2000)
city: Ramat Gan
country: Israel
facility: Sheba Medical Center ( Site 2001)
city: Milano
country: Italy
facility: Istituto Europeo di Oncologia IRCCS ( Site 1404)
state: Lombardia
city: Milan
country: Italy
facility: Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 1401)
state: Lombardia
city: Siena
country: Italy
facility: Azienda Ospedaliero Universitaria Senese-U.O.C. Immunoterapia Oncologica ( Site 1402)
state: Toscana
city: Perugia
country: Italy
facility: AO Santa Maria della Misericordia ( Site 1403)
state: Umbria
city: Napoli
country: Italy
facility: Istituto Nazionale Tumori IRCCS Fondazione Pascale-s.c. melanoma, immunoterapia oncologica e terapi
city: Nagoya
country: Japan
facility: Nagoya University Hospital ( Site 4201)
state: Aichi
city: Nagaizumi-cho,Sunto-gun
country: Japan
facility: Shizuoka Cancer Center ( Site 4202)
state: Shizuoka
city: Chuo
country: Japan
facility: National Cancer Center Hospital ( Site 4200)
state: Tokyo
city: Daegu
country: Korea, Republic of
facility: Kyungpook National University Chilgok Hospital-Hematology/oncology ( Site 3904)
state: Taegu-Kwangyokshi
city: Daejeon
country: Korea, Republic of
facility: Chungnam national university hospital-Department of Internal Medicine ( Site 3903)
state: Taejon-Kwangyokshi
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital-Oncology ( Site 3902)
city: Seoul
country: Korea, Republic of
facility: Severance Hospital, Yonsei University Health System-Medical oncology ( Site 3901)
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center-Division of Hematology/Oncology ( Site 3900)
city: Newtown
country: New Zealand
facility: Capital, Coast and Hutt Valley District - Wellington Regional Hospital ( Site 1502)
state: Wellington
city: Auckland
country: New Zealand
facility: Harbour Cancer & Wellness ( Site 1500)
city: Bydgoszcz
country: Poland
facility: Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 2908)
state: Kujawsko-pomorskie
city: Siedlce
country: Poland
facility: Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 2903)
state: Mazowieckie
city: Warszawa
country: Poland
facility: Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (
state: Mazowieckie
city: Bialystok
country: Poland
facility: Bialostockie Centrum Onkologii ( Site 2905)
state: Podlaskie
city: Gdańsk
country: Poland
facility: Uniwersyteckie Centrum Kliniczne-Klinika Chirurgii Onkologicznej, Transplantacyjnej i Ogólnej ( Site
state: Pomorskie
city: Gliwice
country: Poland
facility: Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 2907)
state: Slaskie
city: Kielce
country: Poland
facility: Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zakl-Klinika Onkologii Klinicznej, Dzial Ch
state: Swietokrzyskie
city: Poznan
country: Poland
facility: Uniwersytecki Szpital Kliniczny w Poznaniu ( Site 2909)
state: Wielkopolskie
city: Szczecin
country: Poland
facility: Zachodniopomorskie Centrum Onkologii ( Site 2904)
state: Zachodniopomorskie
city: Lisbon
country: Portugal
facility: Instituto Português de Oncologia de Lisboa Francisco Gentil ( Site 3601)
state: Lisboa
city: Lisbon
country: Portugal
facility: Unidade Local de Saude de Santa Maria - Hospital de Santa Maria ( Site 3603)
state: Lisboa
city: Lisboa
country: Portugal
facility: Unidade Local de Saude Lisboa Ocidental - Hospital de São Francisco Xavier ( Site 3602)
city: Porto
country: Portugal
facility: Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 3604)
city: Johannesburg
country: South Africa
facility: Medical Oncology Centre of Rosebank ( Site 4106)
state: Gauteng
city: Pretoria
country: South Africa
facility: Wilgers Oncology Centre ( Site 4103)
state: Gauteng
city: Cape Town
country: South Africa
facility: Cape Town Oncology Trials ( Site 4100)
state: Western Cape
city: Barcelona
country: Spain
facility: HOSPITAL CLÍNIC DE BARCELONA-ICHMO- Clinic Institut of Haematological and Oncological diseases ( Sit
state: Cataluna
city: Madrid
country: Spain
facility: Hospital Universitario Ramón y Cajal ( Site 1602)
state: Madrid, Comunidad De
city: Pozuelo de Alarcon
country: Spain
facility: HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID ( Site 1603)
state: Madrid
city: Málaga
country: Spain
facility: H.R.U Málaga - Hospital General-Oncology ( Site 1605)
state: Malaga
city: Valencia
country: Spain
facility: HOSPITAL CLINICO DE VALENCIA ( Site 1604)
state: Valenciana, Comunitat
city: Barcelona
country: Spain
facility: Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 1601)
city: Lund
country: Sweden
facility: Skånes Universitetssjukhus Lund ( Site 3201)
state: Skane Lan
city: Gothenburg
country: Sweden
facility: Sahlgrenska Universitetssjukhuset ( Site 3200)
state: Vastra Gotalands Lan
city: Chur
country: Switzerland
facility: Kantonsspital Graubünden-Medizin ( Site 1703)
state: Grisons
city: Zürich Flughafen
country: Switzerland
facility: UniversitätsSpital Zürich-Dermatology ( Site 1700)
state: Zurich
city: Kaohsiung
country: Taiwan
facility: Chang Gung Memorial Hospital at Kaohsiung (Site 4000)
city: Tainan
country: Taiwan
facility: National Cheng Kung University Hospital-Clinical Trial Center ( Site 4004)
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital (Site 4001)
city: Taoyuan
country: Taiwan
facility: Chang Gung Medical Foundation-Linkou Branch ( Site 4003)
city: Ankara
country: Turkey
facility: Hacettepe Universite Hastaneleri ( Site 3006)
city: Ankara
country: Turkey
facility: Memorial Ankara Hastanesi-Medical Oncology ( Site 3010)
city: Ankara
country: Turkey
facility: Ankara Bilkent Şehir Hastanesi-Medical Oncology ( Site 3002)
city: Istanbul
country: Turkey
facility: Acibadem Universitesi Atakent Hastanesi-Medical Oncology ( Site 3008)
city: Istanbul
country: Turkey
facility: TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 3003)
city: Izmir
country: Turkey
facility: Ege University Medical Faculty Hospital ( Site 3011)
city: Izmir
country: Turkey
facility: I.E.U. Medical Point Hastanesi-Oncology ( Site 3005)
city: Bristol
country: United Kingdom
facility: Bristol Haematology and Oncology Centre ( Site 1811)
state: Bristol, City Of
city: Cambridge
country: United Kingdom
facility: Addenbrooke's Hospital ( Site 1800)
state: Cambridgeshire
city: Cringleford
country: United Kingdom
facility: Norfolk and Norwich University Hospitals NHS Foundation Trust ( Site 1813)
state: England
city: London
country: United Kingdom
facility: ROYAL MARSDEN HOSPITAL (CHELSEA) ( Site 1804)
state: Kensington And Chelsea
city: London
country: United Kingdom
facility: University College London Hospital ( Site 1807)
state: London, City Of
city: Edinburgh
country: United Kingdom
facility: Western General Hospital ( Site 1806)
state: Midlothian
city: Oxford
country: United Kingdom
facility: The Churchill Hospital ( Site 1805)
state: Oxfordshire
city: Leeds
country: United Kingdom
facility: St James's University Hospital-Leeds Cancer Centre ( Site 1808)
city: Manchester
country: United Kingdom
facility: The Christie NHS Foundation Trust ( Site 1814)
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Director
role: STUDY_DIRECTOR
References: